.png)
HB Forms Strategic Partnership With Thailand’s RAM Medical Group
As global trade liberalization deepens and new medical infrastructure accelerates, Chinese medical technology firms are increasingly offering the global market with China's solution that combines both technological innovation and localization. On August 19, Haier Biomedical, a subsidiary of Incaier, entered a strategic partnership with Ramkhamhaeng Hospital Group, one of Thailand's top three private hospital groups, to jointly advance in-depth collaboration in areas such as pharmacy automation and full-scenario smart healthcare solutions.
This partnership, pairing advanced technical solutions with localized services, not only marks another fruitful outcome of Haier Biomedical's "One Country, One Policy" overseas strategy in the Southeast Asian market, but also an important step in its evolution from product exporter to ecosystem co-creator.
Powerful alliance targets Southeast Asia's Urgent Healthcare Upgrade Needs
With a population of 670 million, an aging rate of over 10%, and strong economic growth, Southeast Asia is rapidly emerging as one of the most promising growth markets for the global healthcare industry. Thailand, a regional healthcare hub with a robust healthcare service system and a thriving medical tourism sector, is now in urgent need for upgrades in areas such as pharmacy automation and intelligent medical equipment, creating a golden window of opportunity for Chinese medical technology firms' strategic entry.
As a digital scenario solution provider in life sciences and medical innovation, under Haier Group's Incaier, Haier Biomedical brings extensive technological expertise and localized operational experience in areas such as low-temperature storage, laboratory solutions, smart medication, and blood technology, with its products and solutions now available in over 150 countries and regions worldwide.
The company's core strength lies in its ability to meet the diverse demands of different regional medical markets with "customized technology + localized operations." From its global leading position in medical low-temperature storage equipment to the rapid expansion of solutions for laboratory instruments and consumables, the company has developed a product matrix well-suited for global markets.
RAM Medical Group, Thailand's second-largest private hospital group with 50 operating hospitals and 7,800 beds, has long been dedicated to providing high-quality, affordable healthcare services through the country's most extensive hospital network. The group's recent urgent need to upgrade medical automation aligns perfectly with Haier Biomedical's technological strengths and localized resources.
Under the agreement, the two parties will first pilot a pharmacy automation solution, covering both outpatient pharmacy automation systems and intelligent inventory management modules. They will also develop integrated workflow and analysis tools to enable full-process intelligence in drug storage, transfer, distribution, dispensing, and usage.
This partnership is expected to benefit both local patients and international medical tourists in Thailand, bringing greater efficiency and safety to Southeast Asia's healthcare services.
"One Country, One Policy": From single-point breakthroughs to ecosystem co-creation
This partnership marks more than a business alliance; it represents a major step in Haier Biomedical's "One Country, One Policy" overseas strategy. With Thailand as a pivotal hub, the company is building a market model built on "customized products + localized operations + regional outreach."
Product development is anchored in deep localization, tailoring solutions to the climate, healthcare practices, and regulatory standards of Southeast Asia. Examples include an intelligent cold chain system optimized for tropical medicine storage and a distributed inventory module adapted to private hospital networks—both highlighting Haier Biomedical's strategy of "precise profiling and demand-based customization."
Operationally, the company has transitioned from product sales to service delivery by establishing local operation centers for marketing, logistics, and after-sales services. The new cooperation base with RAM Medical Group will serve as a platform for the regional demonstration and experience-sharing mechanism, welcoming medical institutions from Thailand and neighboring countries, set to accelerate the regional spread of advanced medical technologies.
The latest expansion of cooperation further demonstrates Haier Biomedical's strategic ambition in Southeast Asia. Under the plan, RAM Medical Group will gradually introduce the full range of Incaier products and solutions, covering life sciences, medical innovation, medical equipment, and cell technology. This shift from targeted applications to full healthcare chain coverage also marks a crucial step for Haier Biomedical, moving from single-point breakthroughs to ecosystem co-creation in Southeast Asia.
Setting a benchmark and redefining the value of China's medical technology on the global stage
Against the backdrop of global supply chain restructuring and the rise of "Made-in-China" innovation, the partnership between Haier Biomedical and RAM Medical Group holds strategic significance that goes beyond business. It not only provides a replicable smart healthcare model for the development of Southeast Asia's healthcare industry, but also reshapes the value framework for Chinese medical technology firms seeking to go global. Chinese medical equipment has long been seen as "cost-effective" in global markets. In this partnership, however, Haier Biomedical has introduced China's experience in medical digitalization into Southeast Asia with the guiding principle of "defining standards through technology and creating value through scenarios." With a full upgrade of pharmacy automation, the company has improved overall healthcare service efficiency while creating a closed-loop system for drug safety management. This patient-focused innovation reflects the growing confidence of Chinese medical technology as it evolves from follower to global leader. 
With Thailand serving as a pilot market, Haier Biomedical is expected to take the lead in expanding its footprint across Southeast Asia and tap into the healthcare needs of the region's 670 million people. As the "One Country, One Policy" strategy continues to advance in the future, the company is poised to replicate this model in other emerging markets, leveraging technology and ecosystem coordination to make China's solution a driving force in global healthcare development.
